Avantor Acquires Masterflex Bioprocessing Business from Antylia Scientific

Brookfield Asset Management and CDPQ Acquire Antylia Scientific from GTCR

May 28, 2025

Medical Devices

Brookfield Asset Management's private equity business, together with Brookfield Business Partners and CDPQ, completed the acquisition of Antylia Scientific from GTCR for approximately $1.3–$1.34 billion. Antylia, headquartered in Vernon Hills, Illinois, is a diversified life‑sciences tools manufacturer and distributor serving biopharma, clinical diagnostics and environmental testing markets; the transaction represents a PE exit after a decade of GTCR partnership and transformational growth.

Avantor Acquires Ritter GmbH and Its Affiliates

June 10, 2021

Medical Devices

Avantor, Inc. completed its acquisition of Ritter GmbH and its affiliates, a Germany-based manufacturer of high-precision robotic and liquid-handling consumables, in an all-cash transaction announced in 2021. The deal (upfront equity purchase price approx. €890 million plus potential earnouts) expands Avantor's proprietary offering for diagnostic and drug-discovery workflows and is expected to be immediately accretive to adjusted EPS while enhancing revenue growth and margins.

Halozyme Acquires Antares Pharma for $960M

April 13, 2022

Pharmaceuticals

Halozyme Therapeutics will acquire Antares Pharma for $5.60 per share in cash, valuing Antares at approximately $960 million. The deal, approved unanimously by both boards, is intended to expand Halozyme's drug delivery capabilities by adding Antares' auto-injector platform and commercial specialty products and is expected to be accretive to Halozyme's 2022 revenue and non-GAAP earnings.

Cytiva Acquires Vanrx Pharmasystems

February 1, 2021

Medical Devices

Cytiva has acquired Vanrx Pharmasystems, a Canadian maker of robotic aseptic filling machines, adding drug‑product filling capability to Cytiva’s bioprocessing portfolio. The deal brings Vanrx’s ~120 employees into Cytiva and expands Cytiva’s end‑to‑end “idea to injection” offering for biopharmaceutical manufacturers.

Merck & Co., Inc. Acquires VelosBio Inc.

November 5, 2020

Biotechnology

Merck & Co., Inc. will acquire all outstanding shares of clinical-stage biopharmaceutical company VelosBio for $2.75 billion in cash. The acquisition adds VelosBio's lead investigational antibody-drug conjugate VLS-101 and ROR1-directed pipeline assets to Merck's oncology portfolio and is expected to close by the end of 2020, subject to customary conditions.

ILC Dover Acquires Flexan from Linden Capital Partners

July 26, 2021

Medical Devices

ILC Dover LP has agreed to acquire Flexan, LLC from Linden Capital Partners. Flexan is a global contract manufacturer of high‑precision silicone, thermoplastic, and specialty rubber components primarily serving medical device OEMs; the acquisition expands ILC Dover’s manufacturing capabilities and customer base in medical device components.